<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1666">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05139472</url>
  </required_header>
  <id_info>
    <org_study_id>STU 2018-0311</org_study_id>
    <nct_id>NCT05139472</nct_id>
  </id_info>
  <brief_title>Impact of Empagliflozin on Functional Capacity in Heart Failure With Preserved Ejection Fraction</brief_title>
  <official_title>Impact of Empagliflozin on Functional Capacity in Heart Failure With Preserved Ejection Fraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sodium-Glucose Cotransporter-2 (SGLT-2) inhibitors generally and empagliflozin specifically&#xD;
      have shown cardiovascular benefits in patients with heart failure (HF), but the underlying&#xD;
      mechanisms remain unclear. Empagliflozin use resulted in lower pulmonary artery diastolic&#xD;
      pressures in patients with HF, suggesting a beneficial diuretic effect. Other potential&#xD;
      mechanisms include increased blood volume, decreased blood pressure, and changes in&#xD;
      sympathetic and neuro-hormonal activation.&#xD;
&#xD;
      This study is a single-arm, open label, prospective interventional study of 8 subjects with&#xD;
      heart failure with preserved ejection fraction (HFpEF) and diabetes. Before and after 12&#xD;
      weeks of daily empagliflozin, participants with undergo comprehensive invasive exercise&#xD;
      testing with a right heart catheter. Our goal is to evaluate the effects of empagliflozin on&#xD;
      fitness, assessed by peak VO2, and peak left ventricular filling pressure, assessed by&#xD;
      pulmonary capillary pressure at peak exercise.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-arm, open label, pilot study of 8 subjects with HFpEF and diabetes. The&#xD;
      subjects will undergo screening tests (exercise stress echo and blood work) to evaluate for&#xD;
      potential exclusion criteria and provide familiarization to the exercise protocol. Those&#xD;
      included will undergo an echocardiogram and invasive cardiopulmonary exercise test. This&#xD;
      involves placement of a right heart catheter in the pulmonary artery and undergoing seated,&#xD;
      upright exercise. During the exercise test, the subject's oxygen uptake (VO2), intra-cardiac&#xD;
      pressures (right atrial pressure, pulmonary capillary wedge pressure) and cardiac output (Qc)&#xD;
      will be measured. The subject will take a dose of empagliflozin in the lab and wait for at&#xD;
      least 60 minutes. They will repeat a shortened version of the exercise test in the afternoon.&#xD;
      After baseline testing, each subject will take 10mg empagliflozin daily for 12 weeks. They&#xD;
      will have repeat blood work (specific electrolytes and renal function) 30 days after starting&#xD;
      medication to screen for renal injury. After 12 weeks, they will return for another invasive&#xD;
      cardiopulmonary exercise test and echocardiogram.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 9, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single arm, open label trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Oxygen Uptake</measure>
    <time_frame>12 weeks</time_frame>
    <description>Peak VO2 measured on maximal exercise test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak Pulmonary Capillary Wedge Pressure (PCWP)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Peak PCWP, measured at end-expiration, at the end of maximal exercise test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Primary Endpoints after single dose of empagliflozin</measure>
    <time_frame>1 hour</time_frame>
    <description>Peak VO2 and peak PCWP will be measured after a single dose of empagliflozin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Output at Rest and During Exercise</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke Volume at Rest and During Exercise</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Right Atrial Pressure at Rest and During Exercise</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Capillary Wedge Pressure at Rest and During Submaximal Exercise</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular volumes at rest and during submaximal exercise</measure>
    <time_frame>12 weeks</time_frame>
    <description>Measured by echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin mass, plasma volume, total blood volume</measure>
    <time_frame>12 weeks</time_frame>
    <description>Measured by Carbon Monoxide Rebreathe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic parameters at rest and during submaximal exercise</measure>
    <time_frame>12 weeks</time_frame>
    <description>Measured by echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 minute walk time</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Heart Failure With Preserved Ejection Fraction</condition>
  <condition>Heart Failure, Diastolic</condition>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm of the study will take 10 mg empagliflozin daily for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin 10 MG</intervention_name>
    <description>Daily Empagliflozin</description>
    <arm_group_label>Treatment Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  adults ages 50-85, type 2 diabetes mellitus, and clinical heart failure with ejection&#xD;
             fraction &gt; 50%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  previous hypersensitivity or adverse reaction to SGLT-2 inhibitors, currently treated&#xD;
             with SGLT-2 inhibitor, ejection fraction &lt;50%, chronic kidney disease with glomerular&#xD;
             filtration rate &lt; 45 ml/kg/min, unstable coronary artery disease, significant&#xD;
             arrhythmia, BMI &gt;55 kg/m2 and inability to exercise.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institute for Exercise and Environmental Medicine</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Macnamara, MD</last_name>
      <phone>214-345-4670</phone>
      <email>James.macnamara@utsouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>James P MacNamara, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benjamin D Levine, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>James Macnamara</last_name>
      <email>james.macnamara@utsouthwestern.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 10, 2021</study_first_submitted>
  <study_first_submitted_qc>November 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 1, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>James MacNamara</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Exercise</keyword>
  <keyword>Invasive Exercise Testing</keyword>
  <keyword>SGLT-2 Inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Heart Failure, Diastolic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>De-identified data may be made available upon reasonable request</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

